AU780444B2 - Chlamydia antigens and corresponding DNA fragments and uses thereof - Google Patents

Chlamydia antigens and corresponding DNA fragments and uses thereof Download PDF

Info

Publication number
AU780444B2
AU780444B2 AU43885/00A AU4388500A AU780444B2 AU 780444 B2 AU780444 B2 AU 780444B2 AU 43885/00 A AU43885/00 A AU 43885/00A AU 4388500 A AU4388500 A AU 4388500A AU 780444 B2 AU780444 B2 AU 780444B2
Authority
AU
Australia
Prior art keywords
ala
polypeptide
ser
seq
gin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU43885/00A
Other languages
English (en)
Other versions
AU4388500A (en
Inventor
Pamela Dunn
Andrew D. Murdin
Raymond P. Oomen
Joe Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Ltd
Original Assignee
Aventis Pasteur Ltd
Aventis Pasteur Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pasteur Ltd, Aventis Pasteur Inc filed Critical Aventis Pasteur Ltd
Publication of AU4388500A publication Critical patent/AU4388500A/en
Application granted granted Critical
Publication of AU780444B2 publication Critical patent/AU780444B2/en
Assigned to SANOFI PASTEUR LIMITED reassignment SANOFI PASTEUR LIMITED Amend patent request/document other than specification (104) Assignors: AVENTIS PASTEUR LIMITED
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU43885/00A 1999-05-03 2000-05-03 Chlamydia antigens and corresponding DNA fragments and uses thereof Ceased AU780444B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13227099P 1999-05-03 1999-05-03
US60/132270 1999-05-03
US14127699P 1999-06-30 1999-06-30
US60/141276 1999-06-30
PCT/CA2000/000511 WO2000066739A2 (en) 1999-05-03 2000-05-03 Chlamydia antigens and corresponding dna fragments and uses thereof

Publications (2)

Publication Number Publication Date
AU4388500A AU4388500A (en) 2000-11-17
AU780444B2 true AU780444B2 (en) 2005-03-24

Family

ID=26830227

Family Applications (1)

Application Number Title Priority Date Filing Date
AU43885/00A Ceased AU780444B2 (en) 1999-05-03 2000-05-03 Chlamydia antigens and corresponding DNA fragments and uses thereof

Country Status (8)

Country Link
US (4) US20030095973A1 (enExample)
EP (1) EP1177301B1 (enExample)
JP (1) JP4695763B2 (enExample)
AT (1) ATE375391T1 (enExample)
AU (1) AU780444B2 (enExample)
CA (1) CA2373021A1 (enExample)
DE (1) DE60036698T2 (enExample)
WO (1) WO2000066739A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6686339B1 (en) 1998-08-20 2004-02-03 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
EP1105489A1 (en) 1998-08-20 2001-06-13 Aventis Pasteur Limited Nucleic acid molecules encoding pomp91a protein of chlamydia
AU5366099A (en) 1998-08-20 2000-03-14 Connaught Laboratories Limited Nucleic acid molecules encoding inclusion membrane protein of (chlamydia)
US6649370B1 (en) 1998-10-28 2003-11-18 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US6607730B1 (en) 1998-11-02 2003-08-19 Aventis Pasteur Limited/Aventis Pasteur Limitee Chlamydia antigens and corresponding DNA fragments and uses thereof
AU3790900A (en) 1998-12-01 2000-06-19 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
MXPA01005615A (es) * 1998-12-04 2004-08-19 Univ Manitoba Procedimiento de inmunizacion en dos pasos para proteger contra infeccion por chlamydia.
US20020061848A1 (en) 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
CN100365120C (zh) 1998-12-08 2008-01-30 科里克萨有限公司 用于治疗及诊断衣原体感染的化合物和方法
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
US7297341B1 (en) 1998-12-23 2007-11-20 Sanofi Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
CA2354431A1 (en) 1998-12-23 2000-07-06 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
US6808713B1 (en) 1998-12-28 2004-10-26 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
JP2002541766A (ja) 1998-12-28 2002-12-10 アベンティス、パストゥール、リミテッド クラミジア抗原および対応するｄｎａ断片ならびにその使用
GB9902555D0 (en) 1999-02-05 1999-03-24 Neutec Pharma Plc Medicament
EP2172214A3 (en) 1999-03-12 2011-03-16 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
WO2000066739A2 (en) 1999-05-03 2000-11-09 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
CA2385325C (en) 1999-09-20 2012-04-10 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
US6632663B1 (en) 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
WO2001036455A2 (en) * 1999-11-12 2001-05-25 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
EP1240331B1 (en) 1999-12-22 2010-04-07 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
US20020082402A1 (en) * 2000-04-04 2002-06-27 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
AU2001255596A1 (en) 2000-04-21 2001-11-07 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US20040254130A1 (en) * 2000-05-08 2004-12-16 Murdin Andrew D Chlamydia antigens and corresponding dna fragments and uses thereof
EP1282718B1 (en) 2000-05-08 2006-12-20 Sanofi Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
ATE440861T1 (de) 2000-07-03 2009-09-15 Novartis Vaccines & Diagnostic Immunisierung gegen chlamydia pneumoniae
US20080112965A1 (en) * 2001-10-01 2008-05-15 Aventis Pasteur Limited Chlamydia OMP antigen
WO2010100632A2 (en) 2009-03-06 2010-09-10 Novartis Ag Chlamydia antigens
EP2501396B1 (en) 2009-11-18 2018-04-25 Auburn University Low antigen-dose immunization for maximizing t-helper cell 1 (th1) immunity against disease

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1331443C (en) * 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5283185A (en) * 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
CN100365017C (zh) * 1994-09-20 2008-01-30 日立化成工业株式会社 肺炎衣原体抗原多肽
FR2726764B1 (fr) * 1994-11-14 1997-01-31 Pasteur Merieux Serums Vacc Adjuvant pour composition vaccinale
US5840788A (en) 1997-06-20 1998-11-24 Acushnet Company Ultraviolet light resistant urethane top coat for golf balls
ES2264810T3 (es) * 1997-06-23 2007-01-16 Loke Diagnostics Aps Proteinas de chlamydia pneumoniae expuestas en la superficie.
US7459524B1 (en) * 1997-10-02 2008-12-02 Emergent Product Development Gaithersburg Inc. Chlamydia protein, sequence and uses thereof
KR20010032336A (ko) * 1997-11-21 2001-04-16 브랑디 빠스깔 클라미디아 뉴모니아 게놈 서열과 폴리펩티드, 이의 단편및 이의 용도, 특히, 감염의 진단, 예방 및 치료 용도
ATE480625T1 (de) 1997-11-21 2010-09-15 Merck Serono Biodevelopment Äusseres membranpolypeptid von chlamydia pneumoniae sowie fragmente davon und deren verwendung, insbesondere zur diagnose, prävention und behandlung einer infektion
KR100760221B1 (ko) 1997-11-28 2007-10-30 세로노 제네틱스 인스티튜트 에스.에이. 클라미디아 트라코마티스 게놈 서열과 폴리펩티드, 이의단편 및 이의 용도, 특히, 감염의 진단, 예방 및 치료 용도
US6693087B1 (en) 1998-08-20 2004-02-17 Aventis Pasteur Limited Nucleic acid molecules encoding POMP91A protein of Chlamydia
AU5366099A (en) 1998-08-20 2000-03-14 Connaught Laboratories Limited Nucleic acid molecules encoding inclusion membrane protein of (chlamydia)
EP1129202A2 (en) 1998-10-28 2001-09-05 Aventis Pasteur Limited Chlamydia antigenes and corresponding dna fragments and uses thereof
US6822071B1 (en) * 1998-11-12 2004-11-23 The Regents Of The University Of California Polypeptides from Chlamydia pneumoniae and their use in the diagnosis, prevention and treatment of disease
EP1133572A4 (en) 1998-11-12 2005-06-15 Univ California GENOME SEQUENCE OF CHLAMYDIA PNEUMONIAE
AU3790900A (en) 1998-12-01 2000-06-19 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US20020061848A1 (en) 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
US6565856B1 (en) 1998-12-08 2003-05-20 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
CN100365120C (zh) 1998-12-08 2008-01-30 科里克萨有限公司 用于治疗及诊断衣原体感染的化合物和方法
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
US6808713B1 (en) 1998-12-28 2004-10-26 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
GB9902555D0 (en) 1999-02-05 1999-03-24 Neutec Pharma Plc Medicament
WO2000066739A2 (en) 1999-05-03 2000-11-09 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
CA2385325C (en) 1999-09-20 2012-04-10 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
US6632663B1 (en) 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
EP1240331B1 (en) 1999-12-22 2010-04-07 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
AU2138501A (en) 1999-12-22 2001-07-03 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US20020071831A1 (en) 2000-04-04 2002-06-13 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
US20020082402A1 (en) 2000-04-04 2002-06-27 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
US20030100706A1 (en) 2000-04-04 2003-05-29 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
US20020132994A1 (en) 2000-04-04 2002-09-19 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
US20020094965A1 (en) 2000-04-04 2002-07-18 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
AU2001255596A1 (en) 2000-04-21 2001-11-07 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US20040254130A1 (en) 2000-05-08 2004-12-16 Murdin Andrew D Chlamydia antigens and corresponding dna fragments and uses thereof
EP1282718B1 (en) 2000-05-08 2006-12-20 Sanofi Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
ATE440861T1 (de) 2000-07-03 2009-09-15 Novartis Vaccines & Diagnostic Immunisierung gegen chlamydia pneumoniae

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MELGOSA INFECT. IMMUN. 1994 62(3):880-86 *
TREMB AC. NO. Q927H7 *

Also Published As

Publication number Publication date
US7658934B2 (en) 2010-02-09
US20050202048A1 (en) 2005-09-15
JP2002542827A (ja) 2002-12-17
US7070792B2 (en) 2006-07-04
JP4695763B2 (ja) 2011-06-08
DE60036698T2 (de) 2008-07-24
CA2373021A1 (en) 2000-11-09
EP1177301B1 (en) 2007-10-10
AU4388500A (en) 2000-11-17
US20090155350A1 (en) 2009-06-18
ATE375391T1 (de) 2007-10-15
DE60036698D1 (de) 2007-11-22
US20040086525A1 (en) 2004-05-06
WO2000066739A3 (en) 2001-01-11
WO2000066739A2 (en) 2000-11-09
US20030095973A1 (en) 2003-05-22
US7595058B2 (en) 2009-09-29
EP1177301A2 (en) 2002-02-06

Similar Documents

Publication Publication Date Title
US7658934B2 (en) Chlamydia antigens and protein vaccine
US7736873B2 (en) Chlamydia polypeptides and corresponding DNA fragments and uses thereof
CA2385325C (en) Chlamydia antigens and corresponding dna fragments and uses thereof
WO2001021810A1 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
US7629327B2 (en) Chlamydia 60 Kda CRMP antigens and vaccine uses
US7335370B2 (en) Chlamydia antigens and corresponding DNA fragments and uses thereof
AU774902B2 (en) Chlamydia antigens and corresponding DNA fragments and uses thereof
EP1220924A1 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
WO2001002575A1 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
WO2001021806A1 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
WO2001021802A1 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
WO2001021805A1 (en) Chlamydia antigens and corresponding dna fragments and uses thereof